How Judgment Creates Enduring Value in Life Sciences

Life sciences companies are built under conditions that few other industries face. Value is long dated, risk is scientific and regulatory, and capital markets move in cycles that rarely align with clinical timelines. In this environment, the most important question is not simply how to access capital, but how to build durable value through uncertainty? Companies that endure do so not because of a single financing or exit, but because they make disciplined decisions early, structure intelligently and preserve optionality across a long and uncertain life cycle.

From the earliest days of biotech, it became clear that life sciences could not be served effectively using the same playbooks applied to other industries. These companies are often pre revenue for a decade or more, carry existential regulatory risk, and depend on partnerships and transactions that may unfold over decades. Getting the structure wrong early does not merely slow progress; it can foreclose the future. That reality demands a fundamentally different approach to advising life sciences companies, one grounded in technical focus, life cycle thinking and judgment developed through sustained engagement with the industry.

Over time, much of what is now considered standard in life sciences partnering, venture financings, IPOs and M&A had to be invented in real time. Early frameworks emerged from experience at the deal table, aligning incentives between innovators and capital providers, structuring collaborations that could survive scientific uncertainty, and drafting agreements that balanced control, economics and flexibility. At Cooley, that experience compounds at unusual scale. In the past three years alone, Cooley has advised on more than 2,300 life sciences partnering and licensing matters, supported by a dedicated team of lawyers focused exclusively on life sciences across the US, Europe and Asia. That volume is not about scale for its own sake – it creates pattern recognition. The most effective structures were never designed as static documents. They were designed as constitutions, durable enough to last through multiple inflection points, yet flexible enough to adapt as science, regulation and markets evolve.

Across all transaction types, judgment is the differentiator that matters most. Life sciences leaders choose advisors who can see around corners, understand how today’s decisions will affect tomorrow’s financing or exit, and focus negotiations on what truly drives value. That judgment is institutional. It is built over decades of observing which structures succeed, which fail and where risk actually emerges years after a deal closes.

Cooley’s transactional footprint reinforces that perspective. Over the past six years, Cooley has advised on more than 1,600 M&A transactions with an aggregate value exceeding $735 billion, and it is consistently ranked number one globally for life sciences M&A by deal count. The same is true in the public markets, where Cooley has led more venture backed life sciences IPOs than any other firm for more than 15 years. That depth allows complexity to be simplified, trade offs to be surfaced early and hard advice to be delivered when it matters most.

Ultimately, breakthroughs in life sciences do not happen by accident. They occur when great science is matched with durable structures, sound judgment and teams capable of executing across an entire life cycle. The true measure of success is not a single transaction or discovery, but a repeatable ability to navigate uncertainty, innovate when markets are constrained and create long term value across cycles. For leaders and investors navigating today’s environment, flexibility, foresight, alignment and judgment matter more than ever. These principles underpin why Cooley’s life sciences platform is not merely active in the market, but also trusted by the leaders and investors who are shaping its future.